What is your preferred front line regimen for metastatic squamous cell NSCLC that is PD-L1 and driver mutation negative?   

How do you select between the available treatment options (gemcitabine, docetaxel, paclitaxel, nab-paclitaxel) in combination with platinum? 

Update: KEYNOTE-407 demonstrated improved overall survival with chemo/pembrolizumab vs. chemotherapy alone. How do you now select between the various treatment options?



Answer from: Medical Oncologist at Community Practice